The US FDA has approved Mesoblast's Ryoncil (remestemcel-L-rknd) for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients 2 months and older. …
FDA approves Mesoblast's cell therapy to treat steroid-refractory acute graft-versus-host disease
December 19, 2024 Australian Biotech
Latest Video
New Stories
-
CSL absorbs loss in reset year as investors back its plasma-led recovery
August 18, 2026 - - Latest News -
Vinnies named inaugural partner of Pharmacy Guild Foundation
August 18, 2026 - - Latest News -
Opportunity #2 - AI can democratise HTA and the negotiations must not squander it
August 18, 2026 - - Latest News -
Opportunity #1 - biosimilar policy failure has become impossible to ignore
August 18, 2026 - - Latest News -
Mesoblast completes treatment in pivotal low back pain trial as phase 3 readout approaches
August 17, 2026 - - Australian Biotech -
Dimerix takes control of US development pathway for new kidney injury treatment
August 17, 2026 - - Australian Biotech -
OncoSil secures FDA approval for targeted bile duct cancer device
August 17, 2026 - - Latest News